MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma

Chao-Hua Chiu; Hsiang-Ling Ho; Howard Doong; Yi-Chen Yeh; Mei-Yu Chen; Teh-Ying Chou; Chun-Ming Tsai

doi:10.18632/oncotarget.3511

MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma

Oncotarget ◽

10.18632/oncotarget.3511 ◽

2015 ◽

Vol 6 (10) ◽

pp. 8407-8417 ◽

Cited By ~ 9

Author(s):

Chao-Hua Chiu ◽

Hsiang-Ling Ho ◽

Howard Doong ◽

Yi-Chen Yeh ◽

Mei-Yu Chen ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Poor Response ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors

Thoracic Cancer ◽

10.1111/1759-7714.12814 ◽

2018 ◽

Vol 9 (9) ◽

pp. 1151-1155 ◽

Cited By ~ 3

Author(s):

Zhansheng Jiang ◽

Yu Zhang ◽

Yinli Yang ◽

Zhensong Yue ◽

Zhanyu Pan

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Abstract 742: Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

10.1158/1538-7445.am2015-742 ◽

2015 ◽

Author(s):

Yuho Maki ◽

Shinsuke Hashida ◽

Hiromasa Yamamoto ◽

Kazuhiko Shien ◽

Tomoaki Ohtsuka ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Cell Lines ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Hsp90 Inhibitor ◽

Adenocarcinoma Cell ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma

Current Drug Discovery Technologies ◽

10.2174/1570163813666160524142846 ◽

2016 ◽

Vol 13 (2) ◽

pp. 68-76 ◽

Cited By ~ 6

Author(s):

Akash Verma ◽

Akhil Chopra ◽

Yeo W. Lee ◽

Lavina D. Bharwani ◽

Atasha B. Asmat ◽

...

Keyword(s):

Pleural Effusion ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Malignant Pleural Effusion ◽

Kinase Inhibitors ◽

Talc Pleurodesis ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

An activation of LC3A-mediated autophagy contributes tode novoand acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma

The Journal of Pathology ◽

10.1002/path.4354 ◽

2014 ◽

pp. n/a-n/a ◽

Cited By ~ 9

Author(s):

Kaito Nihira ◽

Yasuhiro Miki ◽

Shinya Iida ◽

Sodai Narumi ◽

Katsuhiko Ono ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2012.07.166 ◽

2012 ◽

Vol 84 (3) ◽

pp. S102

Author(s):

H. Hirata ◽

K. Nakamura ◽

N. Kunitake ◽

Y. Shioyama ◽

T. Sasaki ◽

...

Keyword(s):

Radiation Therapy ◽

Brain Metastases ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors ◽

Egfr Mutant

Download Full-text

Unusual Presentation of Lung Adenocarcinoma With Paraneoplastic Stiff Person Syndrome: Role of EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.03.025 ◽

2019 ◽

Vol 14 (8) ◽

pp. e179-e180

Author(s):

Nawid Sarwari ◽

Yehuda Galili ◽

Ariel Perez ◽

Nicholas Avgeropoulos ◽

Jennifer Tseng

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Unusual Presentation ◽

Stiff Person Syndrome ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors

Cancer Research and Treatment ◽

10.4143/crt.2017.378 ◽

2018 ◽

Vol 50 (3) ◽

pp. 908-916 ◽

Cited By ~ 11

Author(s):

Jiyoul Yang ◽

Ok-Jun Lee ◽

Seung-Myoung Son ◽

Chang Gok Woo ◽

Yusook Jeong ◽

...

Keyword(s):

Pleural Effusion ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Malignant Pleural Effusion ◽

Kinase Inhibitors ◽

Egfr Mutation ◽

Mutation Status ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR

Thoracic Cancer ◽

10.1111/1759-7714.12847 ◽

2018 ◽

Vol 9 (11) ◽

pp. 1398-1405 ◽

Cited By ~ 3

Author(s):

Te-Chun Hsia ◽

Ji-An Liang ◽

Chia-Chin Li ◽

Chun-Ru Chien

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Comparative Effectiveness ◽

Concurrent Chemoradiotherapy ◽

Kinase Inhibitors ◽

Clinical Stage ◽

Stage Iiib ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC

Nature Clinical Practice Oncology ◽

10.1038/ncponc0893 ◽

2007 ◽

Vol 4 (9) ◽

pp. 503-504

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kras Mutation ◽

Kinase Inhibitors ◽

Poor Response ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors

Download Full-text

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.04.020 ◽

2019 ◽

Vol 14 (8) ◽

pp. e157-e159 ◽

Cited By ~ 2

Author(s):

Zhen Zhou ◽

Yi Zhao ◽

Shengping Shen ◽

Linping Gu ◽

Xiaomin Niu ◽

...

Keyword(s):

Combination Therapy ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Clinical Response ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Third Generation ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors ◽

In Trans

Download Full-text